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In low-resource regions, fibrinolytic therapy is often the only option for ST-elevation myocar-
dial infarction (STEMI) patients as primary percutaneous coronary intervention (PCI) is
often not available and patients are hardly transferred to a medical center with PCI capacity
within the first 120 minutes. Chronic kidney disease (CKD) is one of the most frequently
encountered complications of STEMI. However, the evidence for the efficacy of fibrinolytic
therapy in STEMI patients with CKD is still limited. The aim of this study is to test whether
CKD modifies the association between fibrinolytic therapy and short-term major adverse
cardiovascular events (MACEs) among patients with STEMI.
Methods and findings
This is a real-world study analyzing the data from 9508 STEMI patients (mean age: 64.0
±12.4 years; male: 70.1%) in the third phase of Clinical Pathways in Acute Coronary Syn-
dromes program (CPACS-3), which is a large study of the management of acute coronary
syndromes (ACS) in 101 county hospitals without PCI capacity in China. CKD was defined
as an estimated glomerular filtration rate of less than 60 mL/min per 1�73 m2 at the admis-
sion. The primary outcome is short-term MACEs, including all-cause death, recurrent myo-
cardial infarction, or nonfatal stroke. Patients were recruited consecutively between October
2011 and November 2014. Out of them, 1282 patients (13.5%) were classified as having
CKD. Compared with non-CKD patients, CKD patients were less likely to receive fibrinolytic
therapy than non-CKD patients (26.4% vs. 38.9%, P<0.001), more likely to experience a
failed fibrinolytic therapy (32.8% vs. 16.9%), and had a higher risk of short-term MACEs
(19.7% vs. 5.6%). After full adjustment, use of fibrinolytic therapy was associated with a
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significantly lower risk of short-term MACEs in non-CKD patients (relative risk [RR] = 0.87,
95% confidence interval [CI]: 0.76–0.99), but not in CKD patients (P for interaction = 0.026).
Further analysis stratified by the success of fibrinolysis showed that compared with patients
who did not receive fibrinolytic therapy, patients with successful fibrinolysis had a lower risk
of short-term MACEs that was similar between patients with (RR = 0.71, 95% CI: 0.55–0.82)
and without CKD (RR = 0.67, 95% CI: 0.55–0.92), while patients with unsuccessful fibrinoly-
sis had a similarly higher risk in CKD patients (RR = 1.25, 95% CI: 1.09–1.43) and non-CKD
patients (RR = 1.30, 95% CI: 1.13–1.50).
Conclusions
CKD reduced the likelihood of successful fibrinolysis and increased the risk of short-term
MACEs in patients with STEMI. Attention should be paid to how to improve the success rate
of fibrinolytic therapy for STEMI patients with CKD.
Trial registration
The CPACS-3 study was registered on www.clinicaltrials.gov (NCT01398228).
Introduction
Myocardial infarction (MI) remains one of the leading causes of death worldwide [1], and ST-
elevation myocardial infarction (STEMI) is associated with the greatest case-fatality [2]. Inci-
dence rates of STEMI have declined in Europe and the US [2, 3], but significantly increased in
China during the past decade [4]. The latest international and Chinese guidelines recommend
that primary percutaneous coronary intervention (PCI) should be the preferred reperfusion
therapy for STEMI patients within the first 12 hours of symptom onset, and the time to pri-
mary PCI from STEMI diagnosis is recommended to be�120 minutes [2, 3, 5]. However, if
primary PCI cannot be performed within this timeframe or where access to such treatment is
not available, fibrinolytic therapy should be administered to STEMI patients without any con-
traindications [2, 3, 5]. Although PCI is the standard of care for STEMI in economically devel-
oped areas, application of fibrinolysis to the large population of STEMI patients in rural areas
where STEMI patients cannot receive timely primary PCI is still very important.
One of the most frequently encountered co-morbidities of coronary disease is kidney dis-
ease including chronic kidney disease (CKD) and acute kidney injury (AKI), which is esti-
mated to be present in about one-third patients with STEMI in the US [6, 7]. As CKD is
associated with higher risks of bleeding and death, patients with kidney disease are frequently
excluded from major randomized trials of cardiovascular disease [8, 9]. Thus, evidence for the
efficacy and safety of fibrinolytic therapy in STEMI patients with CKD is still limited [10].
The third phase of Clinical Pathways in Acute Coronary Syndromes program (CPACS-3) is
a large study of the management of suspected acute coronary syndromes (ACS) in non-PCI-
capable hospitals in China. Data from this study provide an opportunity to test whether CKD
modifies the associations between fibrinolysis and short-term outcomes after STEMI.
Methods
Study population
CPACS-3 was a stepped-wedge cluster randomized trial among resource-constrained hospitals
in China [11]. The details of the rationale and design have been published previously [12]. The
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objective of CPACS-3 was to determine whether the routine use of a clinical pathway-based,
multifaceted quality of care initiatives (QCI) would lead to a measurable reduction in the
number of short-term major adverse cardiovascular events (MACEs) in patients with ACS
[12]. From eligible hospitals that agreed to participate, ACS patients were consecutively
enrolled in five 6-months cycles. No intervention was applied in the first cycle, after which
hospitals were randomly allocated to commence the intervention in one of the 4 remaining
cycles. The intervention was applied at the level of hospital, with outcomes measured at the
patient level. All patients over 18 years old and with a final diagnosis of ACS at discharge or
death were recruited consecutively within each 6 month cycle. We excluded patients who were
dead on or within 10 minutes of hospital arrival. Between October 2011 and November 2014, a
total of 29 346 patients with ACS were recruited from 101 county hospitals without the capac-
ity to perform onsite PCI, of whom 10 294 patients were diagnosed with STEMI. In these
observational analyses, 786 patients (7.6%) were excluded because of missing admission
data on serum creatinine concentration. The remaining 9508 STEMI patients were included.
The Peking University IRB reviewed and approved the CPACS-3 trial and all participating
patients provided written informed consent. The CPACS-3 study was registered on www.
clinicaltrials.gov (NCT01398228).
Data collection
A dedicated web-based data management system was used to collect data by a trained hospital
staff member who was not involved in of the management of patients. Data for each patient
were collected from the medical record and from survivors prior to hospital discharge, includ-
ing socio-demographic information, symptoms and signs relating to the presenting STEMI,
medical history, electrocardiographic, biomarkers, treatments administered prior to admis-
sion, during hospitalization and at death or hospital discharge, final diagnosis and discharge
status, major clinical events, personal insurance status, and the total cost of hospitalization.
Data quality was maintained through in person and on-line study monitoring activities.
Definitions
CKD was defined as an estimated glomerular filtration rate (eGFR) of less than 60 mL/min per
1�73 m2 at the admission, with eGFR calculated using a modified Modification of Diet in Renal
Disease (MDRD) equation for Chinese: eGFR = 175 × Scr−1.234 × age–0.179 [if female, × 0.79],
where Scr is serum creatinine concentration (in mg/dL) and age in years [13]. Diabetes was
defined by a reported medical history of diabetes, or current use of glucose lowering therapy at
the time of enrollment. Hypertension was defined by a reported medical history of hyperten-
sion, systolic blood pressure (SBP)�140mmHg or diastolic blood pressure�90mmHg on
hospital presentation. Delay to admission was defined as onset-to-door time >2 hours, and
delay to fibrinolytic therapy was defined as onset-to-needle time>12 hours [2, 3, 5]. Successful
fibrinolysis was defined as the presence of any two of the following four criteria, excluding “c
plus d”: a) reduction of elevated ST-segment�50% by ECG achieved within 60 to 90 minutes
of receiving fibrinolytic therapy; b) time to peak cTn concentration�12 hours from symptom
onset and/or time to CK-MB concentration�14 hours from symptom onset; c) significant
relief of chest pain within 2 hours of fibrinolytic therapy; d) presence of reperfusion arrhyth-
mia within 2 to 3 hours of fibrinolytic therapy, including accelerated idioventricular rhythm,
sudden improvement or disappearance of atrioventricular block or bundle branch block,
and transient sinus bradycardia or sino-auricular block with or without hypotension among
patients with inferior wall MI [5, 14]. If thrombolysis was not successful according to above
criteria, then it was considered as a failed fibrinolysis.
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Study endpoints
The primary outcome of the study was short-term MACEs, including all-cause mortality,
recurrent myocardial infarction, or nonfatal stroke. We chose all-cause mortality rather than
cardiac death because our definition of all-cause mortality not only included patients who died
in hospital, but also those who were discharged against medical advice and died within 1 week,
and those who transferred to upper level hospitals but died within 24 hours, as Chinese people
would prefer to die at home after relinquishing curative treatments. The secondary outcome
was all-cause mortality, recurrent MI, stroke, or severe bleeding. All outcome events were
adjudicated by an independent committee according to predefined criteria [12].
Covariates
Covariates that might confound the association between fibrinolysis and short-term MACEs
were selected in our analyses, including age, sex, education, occupation, current smoking,
body mass index, history of diabetes mellitus, hypertension, cardiovascular disease, fibrin-
specific thrombolytic agent, delay to admission, delay to fibrinolytic therapy, SBP lower than
90 mmHg when presenting at hospital, heart rate higher than 100 beats/m when presenting at
hospital, in-hospital use of aspirin, clopidogrel, angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers, β-Blockers, calcium channel blockers, and statins. As CPACS-3
was a trial evaluating the effect of QCI on short-term MACEs, we also included QCI interven-
tion and intervention cycle as covariates.
Statistical analysis
The results are presented as percentages for categorical variables and means ± standard devia-
tions or medians with interquartile ranges for continuous variables. The characteristics of
patients with and without CKD were compared using the t-test, Wilcoxon rank test, or chi-
square test. Modified Poisson regression using PROC GENMOD was performed to assess the
strength of associations (relative risk, RR) between CKD and outcomes, and to identify the
predictors of successful fibrinolysis in patients who received fibrinolytic therapy [15]. We
adopted modified Poisson regression rather than Logistic regression as the primary outcome
was not rare [15]. Generalized estimating equations were used to adjust for clustering within
hospitals. To analyze the data of total participants together, we included CKD (yes, no) and
two dummy variables for fibrinolytic therapy (yes, no; one for CKD patients and one for non-
CKD patients) in the model [16]. To test whether the presence of CKD modified the associa-
tions between fibrinolytic therapy and outcomes, we included CKD, fibrinolytic therapy, and
their interaction term in another model.
To ensure robustness of our findings and reduce the impact of treatment-selection bias,
additional propensity-based subgroup analyses were performed to test the associations
between fibrinolytic therapy and outcomes. In these, patients who did and did not receive
fibrinolytic therapy were matched (1:1) on all covariates in Table 1 except delay to fibrinolytic
therapy and fibrin-specific thrombolytic agent, using the Greedy matching macro [17]. Best
matches are those with the highest digit match on propensity score. First, cases are matched
to controls on 8 digits of the propensity score. For those that do not match, cases are then
matched to controls on 7 digits. The algorithm proceeds sequentially to the lowest digit match
on propensity score (1 digit) [17].
To limit the impact of AKI on our main results, we performed another sensitivity analysis
excluding patients with high risk of AKI, who had an SBP <90 mmHg and/or a heart rate
�100 beats/minute.
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Table 1. Baseline characteristics between participants who did and did not receive fibrinolytic therapy, by the presence of reduced kidney function (eGFR<60 mL/
min/1.73 m2).













Age (years) 65.2±12.4 59.3±11.0 <0.001 72.8±10.5 66.3±10.4 <0.001
Men (%) 3402 (67.7) 2503 (78.2) <0.001 538 (57.0) 221 (65.4) 0.007
eGFR (mL/min/1.73 m2) 101 (82–125) 104 (85–130) <0.001 46 (35–54) 50 (39–55) <0.001
Hospital stay (days) 10 (6–14) 11 (7–14) <0.001 9 (4–13) 8 (2–13) 0.007
Delay to admission (%)� 3324 (66.2) 1582 (49.4) <0.001 637 (67.5) 185 (54.7) <0.001
Delay to fibrinolytic therapy (%)� / 296 (9.3) / / 31 (9.2) /
Fibrin-specific thrombolytic
agent (%)
/ 1272 (39.7) / / 140 (41.4) /
Education�High school (%)� 472 (9.4) 460 (14.4) <0.001 64 (6.8) 53 (15.7) <0.001
Farmer (%)� 3453 (68.7) 1992 (62.2) <0.001 612 (64.8) 202 (59.8) 0.097
Current smoking (%) 1498 (29.8) 1391 (43.5) <0.001 169 (17.9) 77 (22.8) 0.051
History of disease (%)
Hypertension 3098 (61.7) 2032 (63.5) 0.095 633 (67.1) 213 (63.0) 0.179
Diabetes 548 (10.9) 342 (10.7) 0.753 159 (16.8) 54 (16.0) 0.713
Myocardial infarction 328 (6.5) 152 (4.8) <0.001 66 (7.0) 24 (7.1) 0.946
Angina 600 (11.9) 295 (9.2) 0.102 107 (11.3) 32 (9.5) 0.343
Heart Failure 139 (2.8) 31 (1.0) <0.001 69 (7.3) 10 (3.0) 0.004
Stroke 461 (9.2) 222 (6.9) <0.001 121 (12.8) 30 (8.9) 0.054
SBP <90 mmHg (%) 145 (2.9) 154 (4.8) <0.001 79 (8.4) 68 (20.1) <0.001
Heart rate�100 beats/min (%) 644 (12.8) 229 (7.2) <0.001 261 (27.7) 49 (14.5) <0.001
Continuous ECG monitoring (%) 4388 (87.3) 3099 (96.8) <0.001 846 (89.6) 329 (97.3) <0.001
In-hospital medication taken (%)
Aspirin 4874 (97.0) 3182 (99.4) <0.001 882 (93.4) 329 (97.3) 0.007
Clopidogrel 4334 (86.3) 3021 (94.4) <0.001 737 (78.1) 310 (91.7) <0.001
ACEI/ARB 2948 (58.7) 1940 (60.6) 0.081 514 (54.5) 169 (50.0) 0.160
β-Blockers 3267 (65.0) 2240 (70.0) <0.001 473 (50.1) 185 (54.7) 0.144
CCB 399 (7.9) 169 (5.3) <0.001 110 (11.7) 27 (8.0) 0.061
Statins 4718 (93.9) 3100 (96.8) <0.001 830 (87.9) 312 (92.3) 0.027
QCI intervention (%) 2430 (48.4) 1475 (46.1) 0.044 452 (47.9) 156 (46.2) 0.585
Time cycle (%)
1 1060 (21.1) 699 (21.8) 0.110 212 (22.5) 63 (18.6) 0.629
2 946 (18.8) 623 (19.5) 185 (19.6) 69 (20.4)
3 1090 (21.7) 614 (19.2) 178 (18.9) 62 (18.3)
4 994 (19.8) 655 (20.5) 199 (21.1) 77 (22.8)
5 935 (18.6) 610 (19.1) 170 (18.0) 67 (19.8)
The results are presented as mean ± SD, median (quartile 1–quartile 3), or n (%).
�Baseline variable data missing: prehospital delay:1084 case, 11.4%; delay to fibrinolytic therapy, 231 cases, 6.5%; education: 1916 cases, 20.2%; occupation: 438 cases,
4.6%. The cases with missing data were assigned to an additional category.
†Calculated by using a t test, Wilcoxon rank test, or chi-square test.
eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; ECG, electrocardiograph; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin
receptor blockers; CCB, calcium channel blockers; QCI, quality of care initiatives.
The results are presented as mean ± SD, median (quartile 1–quartile 3), or n (%).
https://doi.org/10.1371/journal.pone.0245576.t001
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Statistical analyses were conducted using SAS software, version 9.4 (SAS Institute Inc.,
Cary, NC, USA). All analyses were two-sided, with a P-value of 0.05 considered as the thresh-
old for statistical significance.
Results
Baseline characteristics
The mean age of the 9508 patients with STEMI was 64.0±12.4 years, and 70.1% of participants
were male. The median hospital stay was 10 days (interquartile range: 6 to 14 days). Of these
STEMI patients, 1282 (13.5%) were classified as having CKD, and 3539 (37.2%) patients
received fibrinolytic therapy. CKD Patients were less likely to receive fibrinolytic therapy than
non-CKD patients (26.4% vs. 38.9%, P<0.001). Characteristics of STEMI patients who did and
did not receive fibrinolytic therapy stratified by CKD are shown in Table 1.
Associations between fibrinolytic therapy and outcomes
Crude incidence rates for outcomes by whether received fibrinolytic therapy are shown in S1
Table. Patients with CKD were more likely than those without RFK to experience a short-term
MACE (19.7% vs. 5.6%), death (19.0% vs. 5.2%), recurrent MI (0.9% vs. 0.5%), stroke (0.4% vs.
0.1%), and severe bleeding (1.6% vs. 0.6%). The fully adjusted model in Table 2 shows that
fibrinolytic therapy was significantly associated with a 13% reduction in the risk of short-term
MACEs in patients without CKD but was not in those with CKD. The interaction term of fibri-
nolytic therapy with CKD complication was statistically significant (P = 0.026). We also found
differential associations between fibrinolytic therapy and all-cause mortality in patients with
and without CKD after multivariable adjustment (P for interaction = 0.012, S2 Table). The
associations between fibrinolytic therapy and other secondary outcomes were not analyzed
using regression analysis because of the small number of events.
Association of fibrinolytic therapy with clinical outcomes stratified by the
success/failure of fibrinolytic therapy
Among patients who received fibrinolytic therapy, fibrinolysis was classified as successful in
67.2% with and 83.1% without CKD, respectively. Our further analyses found that the success
Table 2. Associations between fibrinolytic therapy and the risk of short-term major adverse cardiovascular events among patients with and without reduced kidney
function (eGFR<60 mL/min/1.73 m2).
eGFR�60 mL/min/1.73 m2 (n = 8226) eGFR <60 mL/min/1.73 m2 (n = 1282) P for interaction
RR (95% CI) P value RR (95% CI) P value
Model 1�
No fibrinolysis Ref / Ref / /
Fibrinolysis 0.68 (0.52 to 0.89) 0.006 1.03 (0.74 to 1.43) 0.866 0.005
Model 2†
No fibrinolysis Ref / Ref /
Fibrinolysis 0.87 (0.76 to 0.99) 0.034 1.02 (0.87 to 1.18) 0.846 0.026
�Adjusted for age, sex, intervention, cycle, fibrin-specific thrombolytic agent, delay to admission, and delay to fibrinolytic therapy.
†Further adjusted for eGFR, education, occupation, current smoking, body mass index, history of diabetes mellitus, hypertension, cardiovascular disease, systolic blood
pressure lower than 90 mmHg when presenting at hospital, heart rate higher than 100 beats/m when presenting at hospital, in-hospital use of aspirin, clopidogrel,
angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-Blockers, calcium channel blockers, and statins.
eGFR, estimated glomerular filtration rate; RR, relative risk; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0245576.t002
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of fibrinolysis was associated with a lower risk of short-term MACEs, while the failure of fibri-
nolysis was associated with a higher risk, compared with patients not receiving fibrinolytic
therapy (Table 3). After full adjustment (Fig 1), neither association was modified by renal func-
tion. The same results were found for all-cause mortality (see S3 Table).
Prediction models for successful fibrinolysis
We further fit models on the success of fibrinolysis with its associated factors. The success of
fibrinolysis was significantly associated with eGFR, thrombolytic agent, delay to fibrinolytic
therapy, current smoking, high heart rate, and education in patients without CKD (Table 4).
In patients with CKD, eGFR, thrombolytic agent, high heart rate, and education were still sig-
nificantly associated with the success of fibrinolysis (Table 4).
Sensitivity analysis
The propensity-score matching identified 588 patients with and 5502 patients without CKD.
Baseline characteristics were comparable between patients treated with fibrinolysis and those
who were not (S4 Table). The point estimators of the RR obtained using propensity score-
matched subgroup were comparable with those from the main analyses, but the smaller sample
size leads to wider 95% CIs. Thus, the association between fibrinolytic therapy and short-term
MACEs and the modified effect of CKD were not significant anymore (S5 and S6 Tables). The
associations of success/failure of fibrinolysis with short-term MACEs were still significant, and
the modified effect of CKD on the associations remains non-significant (S7 and S8 Tables).
To limit the impact of AKI on our main results, we also performed analysis excluding 1565
participants with SBP<90 mmHg and/or heart rate�100 beats/minute, and this sensitivity
analysis yielded similar results (S9 and S10 Tables).
Discussion
The primary findings of this real-world study were that: (a) CKD modified the association
between fibrinolytic therapy and short-term MACEs; (b) After fixing the status of the success
of fibrinolytic therapy, CKD did not modify the above associations anymore. These findings
strongly inform that future attentions should be paid to further optimize fibrinolytic therapy
and increase the success rate among STEMI patients with CKD. On the one hand, guidelines
for the management of patients with STEMI should recommend clinicians concern eGFR
Table 3. Crude incidence rates of short-term outcomes by no, failed, and successful fibrinolysis, among patients with and without reduced kidney function (eGFR
<60 mL/min/1.73 m2).













MACEs (%) 315 (6.3) 69 (2.6) 80 (14.8) 177 (18.8) 21 (9.3) 54 (48.7)
All-cause
mortality (%)
295 (5.9) 56 (2.1) 77 (14.2) 169 (17.9) 20 (8.8) 54 (48.7)
Recurrent MI (%) 21 (0.4) 15 (0.6) 5 (0.9) 7 (0.7) 2 (0.9) 3 (2.7)
Stroke (%) 7 (0.1) 2 (0.1) 1 (0.2) 5 (0.5) 0 (0.0) 0 (0.0)
Severe bleeding
(%)
22 (0.4) 19 (0.7) 5 (0.9) 12 (1.3) 4 (1.8) 5 (4.5)
The results are presented as n (%).
eGFR, estimated glomerular filtration rate; MACEs, major adverse cardiovascular events; MI, myocardial infarction.
https://doi.org/10.1371/journal.pone.0245576.t003
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before fibrinolysis in clinical practice. To the best of our knowledge, this is one of the largest
observational studies exploring the associations between fibrinolytic therapy and short-term
outcomes among STEMI patients with and without CKD.
In Western countries, the incidence rate of STEMI is decreasing in recent decades. The age-
and sex-adjusted incidence rates of STEMI decreased from 133 per 100 000 in 1999 to 50 per
100 000 in 2008 among the US population [3]. In Europe, an overall trend for a reduction in
the incidence rate of STEMI has also been observed [2]. The incidence rate ranged from 43 to
Fig 1. Associations of successful and failed fibrinolysis with the risk of short-term major adverse cardiovascular events (MACEs) among patients with and
without chronic kidney disease (CKD, eGFR<60 mL/min/1.73 m2), compared with those who did not receive fibrinolytic therapy. �Adjusted for age, sex,
intervention, cycle, fibrin-specific thrombolytic agent, delay to admission, delay to fibrinolytic therapy, eGFR, education, occupation, current smoking, body mass
index, history of diabetes mellitus, hypertension, cardiovascular disease, systolic blood pressure lower than 90 mmHg when presenting at hospital, heart rate higher
than 100 beats/m when presenting at hospital, in-hospital use of aspirin, clopidogrel, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-
Blockers, calcium channel blockers, and statins. eGFR, estimated glomerular filtration rate; RR, relative risk; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0245576.g001
Table 4. Prediction models for successful fibrinolysis in patients who received fibrinolytic therapy among patients with and without reduced kidney function
(eGFR<60 mL/min/1.73 m2).
Predictors eGFR�60 mL/min/1.73 m2 (n = 3201)� eGFR <60 mL/min/1.73 m2 (n = 338)� ,†
β RR (95% CI) P value β RR (95% CI) P value
Intercept –0.320 / <0.001 –0.713 / <0.001
eGFR, per 10 mL/min/1.73 m2 in increase 0.007 1.01 (1.00 to 1.01) <0.001 0.059 1.06 (1.00 to 1.13) 0.068
Fibrin-specific thrombolytic agent (yes vs. no) 0.103 1.11 (1.06 to 1.16) <0.001 0.160 1.17 (1.02 to 1.34) 0.022
Delay to fibrinolytic therapy (yes vs. no) –0.127 0.88 (0.83 to 0.94) <0.001 –0.261 0.77 (0.53 to 1.12) 0.171
Current smoking (yes vs. no) 0.053 1.05 (1.02 to 1.09) <0.001 0.048 1.05 (0.92 to 1.22) 0.534
Heart rate�100 beats/m (yes vs. no) –0.146 0.86 (0.79 to 0.94) 0.001 –0.338 0.71 (0.54 to 0.95) 0.019
Education�High school (yes vs. no) 0.068 1.07 (1.03 to 1.09) 0.001 0.144 1.15 (1.00 to 1.34) 0.054
�The models excluded age, sex, intervention, cycle, delay to admission, occupation, body mass index, history of hypertension, diabetes, cardiovascular disease, and
systolic blood pressure lower than 90 mmHg when presenting at hospital, as these variables were not significant.
†The significant predictors in patients without reduced kidney function were still included in this model.
eGFR, estimated glomerular filtration rate; RR, relative risk; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0245576.t004
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144 per 100 000 per year in European countries [2]. Conversely, the incidence rate of STEMI
in China has substantially increased in recent years. The China PEACE-Retrospective Acute
Myocardial Infarction Study reported that estimated national rates of hospital admission for
STEMI per 100 000 people increased from 3�5 in 2001, to 7�9 in 2006, to 15�4 in 2011. If this
keeps increasing, it is reasonable to expect that the incidence of STEMI in China will approach
or even exceed that in Western countries. Therefore, assessment of fibrinolysis to the large
population of STEMI patients in rural area of China and other developing countries in which
STEMI patients cannot receive timely primary PCI is still significant and the impact of CKD
on outcomes is relevant to clinical practice.
There is no specific recommendation of fibrinolytic therapy for patients with kidney disease
in the latest guidelines for the management of STEMI [2, 3, 5], as few randomized controlled
trials evaluated the treatment effect of the fibrinolysis in the subgroup of STEMI patients with
CKD. This is one of the key reasons why STEMI patients presenting with CKD are less likely
to receive fibrinolytic therapy [6, 10]. Consistent with our results, previous observational stud-
ies have reported that reperfusion rate was lower in STEMI patients with renal dysfunction
[6], and highlighted the association between renal function and subsequent mortality rate in
patients receiving fibrinolytic therapy [18–20]. However, whether CKD modifies the associa-
tion between fibrinolytic therapy and consequent mortality was still unclear. In this large-scale
study, we found that the strength of association between receipt of reperfusion therapy with
fibrinolysis and short-term MACEs was significantly different in patients with and without
CKD, which provides evidence and fills this gap to some extent. However, considering the
nature limitations of observational study, randomized clinical trials performed in patients with
CKD will be necessary to accurately evaluate the efficacy and safety of fibrinolytic therapy. For
example, trials comparing the efficacy of PCI versus fibrin-specific thrombolytic agents on out-
comes among patients with STEMI and CKD.
In current study, we found that successful fibrinolysis occurred less frequently in patients
with CKD, likely-contributing to a higher risk of short-term MACEs. Our analyses further eluci-
dated that CKD does not actually modify the relationships between successful and failed fibrino-
lysis with short-term MACEs. Therefore, the key question becomes how to increase the success
rate of fibrinolytic therapy in STEMI patients with CKD. In order to answer this question, we
built the prediction models of successful fibrinolysis and identified that eGFR, thrombolytic
agent, high heart rate, and education were the crucial predictors in both groups. The success
rate was only 67.2% in patients with CKD, while the rate was 83.1% in those without. When
analysis was restricted to patients with CKD who had an eGFR�30 mL/min/1.73 m2, received a
fibrin-specific thrombolytic agent (tenecteplase or alteplase), had a heart rate<100 beats/m, and
had been educated�high school, the success rate of fibrinolytic therapy was 87.5%.
Consistent with previous studies [6, 20], our study also found that patients with CKD were
associated with a higher risk of bleeding events, which is another important challenging situa-
tion for clinicians to make choices regarding fibrinolytic therapy. Unfortunately, we cannot
analyze the association between fibrinolytic therapy and severe bleeding events using regres-
sion analysis because of the small number of events. Further studies are needed to evaluate the
safety of fibrinolytic therapy in STEMI patients with CKD.
Several underlying mechanisms may account for that CKD patients had a higher rate of
failed fibrinolysis. Firstly, hypofibrinolysis has been well documented in patients with renal
insufficiency and end-stage renal disease, which might lead to the higher rate of failed fibrino-
lysis [21]. A fibrin-specific thrombolytic agent should be the priority selection for CKD
patients accepting fibrinolytic therapy. Therefore, clinicians should distinguish patients with
known renal insufficiency at the time of fibrinolysis, from patients without renal insufficiency
before deciding fibrinolysis. Secondly, CKD patients had more diffuse coronary artery disease
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with a higher thrombotic burden than non-CKD patients [22]. Thirdly, CKD was associated
with many of risk factors, such as diabetes, hypertension, and obesity, which might result in
failed fibrinolysis [22].
Our study has several strengths. First of all, this is a large-scale, real-world study conducted
in STEMI patients who received conservative treatments in non-PCI-capable hospitals. The
primary and secondary endpoints were adjudicated by the independent committee, and the
study process was closely monitored by a dedicated quality control team. In spite of these, our
findings should be interpreted cautiously in the context of some potential limitations. First, the
most important limitation is that this is an observational study of a treatment efficacy question.
The possibility of residual confounding cannot be ruled out even after adjustment for a number
of potential confounders. Although propensity score-matched subgroup analyses yielded simi-
lar results, unmeasured covariates might have influenced our results. Therefore, we are not able
to infer any definite causal relationships due to the observational nature. Second, serum creati-
nine concentrations were measured at admission, thus we are not able to distinguish between
CKD and AKI. Previous studies have shown that the underlining mechanisms between the
two kidney diseases and consequent adverse events after MI might be different [7]. Although
the sensitivity analysis excluding patients with high risk of AKI shows the similar results, the
impact of AKI on our main results cannot be ruled out. Third, there is a possibility of selection
bias, as 786 participants (7.6%) were excluded from the study because of missing data on serum
creatinine concentration. As shown in S11 Table, the median hospital stay was significantly
shorter and all-cause mortality was significantly higher in the 786 patients, which means that
patients with absent creatinine were likely to have died before blood could be drawn. Therefore,
there is a threat to the external validity of estimates and might limit the generalization of pres-
ent findings to the original population. Fourth, the prediction models derived from this study
have not been validated in an independent cohort. Finally, this study was conducted in non-
PCI-capable hospitals in rural China, which highlights the need for caution in generalizing
findings to other populations.
In conclusion, this real-world study suggests that CKD reduced the likelihood of successful
fibrinolysis and increased the risk of short-term MACEs in patients with STEMI. Kidney func-
tion should be evaluated before performing fibrinolysis, and a fibrin-specific thrombolytic
agent should be the priority selection for CKD patients when PCI is not available. Clinicians
and researches should pay attention to developing new methods and techniques to improve
the success rate of fibrinolytic therapy for STEMI patients with CKD. Randomized clinical tri-
als performed in patients with STEMI and CKD will be necessary to accurately evaluate the
efficacy and safety of intervention therapies.
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